Document Detail


A Prospective, Single-Blind, Multicenter, Dose Escalation Study of Intracoronary iNOS Lipoplex (CAR-MP583) Gene Therapy for the Prevention of Restenosis in Patients with de novo or Restenotic Coronary Artery Lesion (REGENT I Extension).
MedLine Citation:
PMID:  21083499     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Abstract Neointimal hyperplasia causing recurrent stenosis is a limitation of the clinical utility of percutaneous transluminal coronary interventions (PCI). Nitric oxide (NO) inhibits smooth muscle cell proliferation, platelet activation, and inflammatory responses, all of which have been implicated in the pathogenesis of restenosis. In animals, neointimal proliferation after balloon injury has been shown to be effectively reduced by gene transfer of the inducible NO synthase (iNOS). The primary objective of this first multicenter, prospective, single-blind, dose escalation study was to obtain safety and tolerability information of the iNOS lipoplex (CAR-MP583) gene therapy for reducing restenosis following PCI. Local coronary intramural CAR-MP583 delivery was achieved using the Infiltrator balloon catheter. A total of 30 patients were treated in the study (six patients, 0.5 μg; six patients, 2.0 μg; six patients, 5.0 μg; and 12 patients, 10 μg). There were no complications related to local application of CAR-MP583. In one patient, PCI procedure-related transient vessel occlusion occurred with consecutive troponin elevation. There were no signs of inflammatory responses or hepatic or renal toxicity. No dose relationship was seen with regard to adverse events across the dose groups. Thus, coronary intramural lipoplex-enhanced iNOS gene therapy during PCI is feasible and appears to be safe. These initial clinical results are encouraging to support further clinical research, in particular in conjunction with new local drug delivery technologies.
Authors:
Heiko E von der Leyen; Andreas Mügge; Christoph Hanefeld; Christian W Hamm; Mathias Rau; Hans J Rupprecht; Andreas M Zeiher; Stephan Fichtlscherer
Related Documents :
19608479 - Tryton i, first-in-man (fim) study: six month clinical and angiographic outcome, analys...
24168009 - Intramural leoimyoma without endometrial cavity distortion may negatively affect the ic...
19920959 - Clopidogrel-taking behavior by drug-eluting stent patients: discontinuers versus contin...
12384629 - Drug-eluting stents: clinical experiences and perspectives.
23689739 - Carbetocin versus sublingual misoprostol plus oxytocin infusion for prevention of postp...
17696619 - Sirolimus-eluting versus bare-metal low-profile stent for renal artery treatment (great...
12887439 - Identifying potential surgical candidates in patients with evidence of bitemporal epile...
19912719 - Treatment of symptomatic incurved toenail with a new device.
22841439 - A new classification of bronchial anastomosis after sleeve lobectomy.
Publication Detail:
Type:  Journal Article     Date:  2011-02-26
Journal Detail:
Title:  Human gene therapy     Volume:  22     ISSN:  1557-7422     ISO Abbreviation:  Hum. Gene Ther.     Publication Date:  2011 Aug 
Date Detail:
Created Date:  2011-08-23     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9008950     Medline TA:  Hum Gene Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  951-8     Citation Subset:  IM    
Affiliation:
1 Hannover Clinical Trial Center GmbH , Hannover, Germany .
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Dried blood spots in HIV monitoring: applications in resource-limited settings.
Next Document:  Identification and characterization of adenovirus early region 1B-associated protein 5 as a surface ...